Related Experiment Video
Updated: Oct 8, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Expanding the LDL-C criterion for suspected homozygous familial hypercholesterolemia to include treated and imputed
G B John Mancini1, Frederick J Raal2
1Centre for Cardiovascular Innovation, Dilawri Cardiovascular Institute, Division of Cardiology, University of British Columbia (John Mancini), Vancouver, Canada.
Abstract:
Homozygous familial hypercholesterolemia (HoFH) remains underdiagnosed worldwide. Cases may not be suspected when family history, physical manifestations, and untreated low-density lipoprotein-cholesterol (LDL-C) levels are unknown or when treated LDL-C levels do not meet current accepted criteria. The latter can be overcome through the application of a validated algorithm for the calculation of an imputed, pretreatment LDL-C based on treated LDL-C considered in the context and the drugs/dosages used to achieve that value. A study of this approach recently provides justification for expansion of the LDL-C criterion for suspected HoFH to be altered to include treated, untreated, or imputed LDL-C >10 mmol/L.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Lipid-Lowering Drugs: Statins and Miscellaneous Agents